Search

Your search keyword '"Bahce, I."' showing total 258 results
Start Over Author "Bahce, I."
258 results on '"Bahce, I."'

10. OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer

Author

Houda, I., primary, Bahce, I., additional, Dickhoff, C., additional, Kroese, T.E., additional, Kroeze, S.G.C., additional, Mariolo, A.V., additional, Tagliamento, M., additional, Moliner, L., additional, Brandao, M., additional, Edwards, J., additional, Opitz, I., additional, Faivre-Finn, C., additional, de Ruysscher, D., additional, Remon, J., additional, Berghmans, T., additional, Dingemans, A.-M.C., additional, Besse, B., additional, and Hendriks, L.E.L., additional

Published
2023
Full Text
View/download PDF

11. P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel

Author

Brandao, M., primary, Prisciandaro, E., additional, Xenophontos, E., additional, Mariolo, A., additional, Sadeghi, A.H., additional, Filippi, A.R., additional, Levy, A., additional, Bandura, A., additional, Caramella, C., additional, Dickhoff, C., additional, de Margerie-Mellon, C., additional, Faivre-Finn, C., additional, Portik, D., additional, Sanchez-Lorente, D., additional, De Ruysscher, D., additional, Smit, E., additional, Gobbini, E., additional, Fadel, E., additional, Ruffini, E., additional, Olmetto, E., additional, Cortiula, F., additional, Bahce, I., additional, Houda, I., additional, Opitz, I., additional, Naidoo, J., additional, Edwards, J., additional, Remon, J., additional, Benitez, J.C., additional, Trujillo, J.C., additional, Derks, J., additional, Amrane, K., additional, Hartemink, K., additional, Stathopoulos, K., additional, Hendriks, L., additional, Iglesias, M., additional, Occhipinti, M., additional, Guckenberger, M., additional, Giaj Levra, N., additional, Girard, N., additional, Reguart, N., additional, Mercier, O., additional, Bironzo, P., additional, Hofman, P., additional, Horsleben Petersen, R., additional, De Angelis, R., additional, Abgral, R., additional, Terrisse, S., additional, Popat, S., additional, Pierret, T., additional, Gerriet Blum, T., additional, Ricardi, U., additional, Dionisi, V., additional, Berghmans, T., additional, and Dingemans, A.-M., additional

Published
2023
Full Text
View/download PDF

13. The landscape of cell-free mitochondrial DNA in liquid biopsy for cancer detection

Author

van der Pol, Y, Moldovan, N, Ramaker, J, Bootsma, S, Lenos, KJ, Vermeulen, L, Sandhu, S, Bahce, I, Pegtel, DM, Wong, SQ, Dawson, S-J, Chandrananda, D, Mouliere, F, van der Pol, Y, Moldovan, N, Ramaker, J, Bootsma, S, Lenos, KJ, Vermeulen, L, Sandhu, S, Bahce, I, Pegtel, DM, Wong, SQ, Dawson, S-J, Chandrananda, D, and Mouliere, F

Abstract

BACKGROUND: Existing methods to detect tumor signal in liquid biopsy have focused on the analysis of nuclear cell-free DNA (cfDNA). However, non-nuclear cfDNA and in particular mitochondrial DNA (mtDNA) has been understudied. We hypothesize that an increase in mtDNA in plasma could reflect the presence of cancer, and that leveraging cell-free mtDNA could enhance cancer detection. RESULTS: We survey 203 healthy and 664 cancer plasma samples from three collection centers covering 12 cancer types with whole genome sequencing to catalogue the plasma mtDNA fraction. The mtDNA fraction is increased in individuals with cholangiocarcinoma, colorectal, liver, pancreatic, or prostate cancer, in comparison to that in healthy individuals. We detect almost no increase of mtDNA fraction in individuals with other cancer types. The mtDNA fraction in plasma correlates with the cfDNA tumor fraction as determined by somatic mutations and/or copy number aberrations. However, the mtDNA fraction is also elevated in a fraction of patients without an apparent increase in tumor-derived cfDNA. A predictive model integrating mtDNA and copy number analysis increases the area under the curve (AUC) from 0.73 when using copy number alterations alone to an AUC of 0.81. CONCLUSIONS: The mtDNA signal retrieved by whole genome sequencing has the potential to boost the detection of cancer when combined with other tumor-derived signals in liquid biopsies.

Published
2023

16. 1786O BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study.

Author

Kalinka, E., Bahce, I., Navarro Mendivil, A.F., Ready, N., Chu, Q.S-C., Sugawara, S., Sibille, A., Provencio Pulla, M., Johnson, M.L., Hiltermann, J.T.J.N., Ciuleanu, T-E., Dziadziuszko, R., Santo, A., Zhang, Y., Liu, Y., Sarmiento, R., Tannenbaum-Dvir, S., Ojalvo, L., Wu, J., and O'Byrne, K.J.

Subjects
*SMALL cell lung cancer, *CARBOPLATIN, *NIVOLUMAB, *ETOPOSIDE
Published
2024
Full Text
View/download PDF

17. 950O Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial

Author

Bahce, I., primary, Dickhoff, C., additional, Schneiders, F.L., additional, Veltman, J., additional, Heineman, D.J., additional, Hashemi, S., additional, Fransen, M., additional, Vrijmoet, A., additional, Houda, I., additional, Ulas, E., additional, van de Ven, P., additional, Bouwhuis, N., additional, Meijboom, L., additional, Oprea-Lager, D., additional, Garcia Vallejo, J., additional, de Gruijl, T.D., additional, Radonic, T., additional, and Senan, S., additional

Published
2022
Full Text
View/download PDF

18. 27P Influence of single nucleotide polymorphisms (SNPs) in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer

Author

Veerman, M.G.D., primary, Boosman, R., additional, Jebbink, M., additional, Oomen-de Hoop, E., additional, van der Wekken, A.J., additional, Bahce, I., additional, Hendriks, L., additional, Steendam, C.M.J., additional, de Jonge, E., additional, Koolen, S.L., additional, van Schaik, R.H.N., additional, Smit, E.F., additional, Dingemans, A-M.C., additional, Huitema, A., additional, and Mathijssen, R.H., additional

Published
2022
Full Text
View/download PDF

19. 1020P Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: The RECLAIM study

Author

Bahce, I., primary, Schneiders, F.L., additional, Hashemi, S., additional, Veltman, J., additional, Daniels, H., additional, Fransen, M., additional, Radonic, T., additional, Ulas, E., additional, Houda, I., additional, Barlo, N., additional, Disselhorst, M., additional, van Laren, M., additional, Tiemessen, M., additional, Tarasevych, S., additional, van Haarst, J.M.M., additional, van Tilburg, P., additional, Kunst, P., additional, Moons-Pasic, A., additional, de Gruijl, T.D., additional, and Senan, S., additional

Published
2022
Full Text
View/download PDF

21. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Author

Niemeijer, A. N., Leung, D., Huisman, M. C., Bahce, I., Hoekstra, O. S., van Dongen, G. A. M. S., Boellaard, R., Du, S., Hayes, W., Smith, R., Windhorst, A. D., Hendrikse, N. H., Poot, A., Vugts, D. J., Thunnissen, E., Morin, P., Lipovsek, D., Donnelly, D. J., Bonacorsi, S. J., Velasquez, L. M., de Gruijl, T. D., Smit, E. F., and de Langen, A. J.

Published
2018
Full Text
View/download PDF

23. Detection and localization of early- and late-stage cancers using platelet RNA

Author

Veld, S., Arkani, M., Post, E., Antunes-Ferreira, M., D'Ambrosi, S., Vessies, D.C.L., Vermunt, L., Vancura, A., Muller, Mirte, Niemeijer, A.N., Tannous, J., Meijer, L.L., Large, T.Y. Le, Mantini, G., Wondergem, N.E., Heinhuis, K.M., Wilpe, S. van, Smits, Josien, Drees, E.E.E., Roos, E., Leurs, C.E., Fat, L.A. Tjon Kon, Lelij, E.J. van der, Dwarshuis, G., Kamphuis, M.J., Visser, Leonie N.C., Harting, R., Gregory, A., Schweiger, M.W., Wedekind, L.E., Ramaker, J., Zwaan, K., Verschueren, H., Bahce, I, Langen, A.J. de, Smit, E.F., Heuvel, M.M. van den, Hartemink, K.J., Kuijpers, M.J., Egbrink, M.G.A. Oude, Griffioen, A.W., Rossel, R., Hiltermann, T.J.N., Lee-Lewandrowski, E., Lewandrowski, K.B., Hamer, P.C., Kouwenhoven, M., Reijneveld, J.C., Leenders, W.P.J., Hoeben, A., Verdonck-de Leeuw, I.M., Leemans, C.Rene, Baatenburg de Jong, R.J., Terhaard, Chris H. J., Takes, R.P., Langendijk, J.A., Jager, S.C. de, Kraaijeveld, A.O., Pasterkamp, G., Smits, M., Schalken, J.A., Łapińska-Szumczyk, S., Łojkowska, A., Żaczek, A.J., Lokhorst, H., Donk, N. van de, Nijhof, I., Prins, H.J., Zijlstra, J.M., Idema, S., Baayen, J.C., Teunissen, C.E., Killestein, J., Besselink, M.G.H., Brammen, L., Bachleitner-Hofmann, T., Mateen, F., Plukker, J.T., Heger, M., Mast, Q. de, Lisman, T., Pegtel, D.M., Bogaard, H.J., Jassem, J., Supernat, A., Mehra, N., Gerritsen, W.R., Kroon, C.D. de, Lok, C. A. R., Piek, J.M.J., Steeghs, N., Houdt, W.J. van, Brakenhoff, R.H., Sonke, G.S., Verheul, H.M.W., Giovannetti, E., Kazemier, G., Sabrkhany, S., Schuuring, E., Sistermans, E.A., Veld, S., Arkani, M., Post, E., Antunes-Ferreira, M., D'Ambrosi, S., Vessies, D.C.L., Vermunt, L., Vancura, A., Muller, Mirte, Niemeijer, A.N., Tannous, J., Meijer, L.L., Large, T.Y. Le, Mantini, G., Wondergem, N.E., Heinhuis, K.M., Wilpe, S. van, Smits, Josien, Drees, E.E.E., Roos, E., Leurs, C.E., Fat, L.A. Tjon Kon, Lelij, E.J. van der, Dwarshuis, G., Kamphuis, M.J., Visser, Leonie N.C., Harting, R., Gregory, A., Schweiger, M.W., Wedekind, L.E., Ramaker, J., Zwaan, K., Verschueren, H., Bahce, I, Langen, A.J. de, Smit, E.F., Heuvel, M.M. van den, Hartemink, K.J., Kuijpers, M.J., Egbrink, M.G.A. Oude, Griffioen, A.W., Rossel, R., Hiltermann, T.J.N., Lee-Lewandrowski, E., Lewandrowski, K.B., Hamer, P.C., Kouwenhoven, M., Reijneveld, J.C., Leenders, W.P.J., Hoeben, A., Verdonck-de Leeuw, I.M., Leemans, C.Rene, Baatenburg de Jong, R.J., Terhaard, Chris H. J., Takes, R.P., Langendijk, J.A., Jager, S.C. de, Kraaijeveld, A.O., Pasterkamp, G., Smits, M., Schalken, J.A., Łapińska-Szumczyk, S., Łojkowska, A., Żaczek, A.J., Lokhorst, H., Donk, N. van de, Nijhof, I., Prins, H.J., Zijlstra, J.M., Idema, S., Baayen, J.C., Teunissen, C.E., Killestein, J., Besselink, M.G.H., Brammen, L., Bachleitner-Hofmann, T., Mateen, F., Plukker, J.T., Heger, M., Mast, Q. de, Lisman, T., Pegtel, D.M., Bogaard, H.J., Jassem, J., Supernat, A., Mehra, N., Gerritsen, W.R., Kroon, C.D. de, Lok, C. A. R., Piek, J.M.J., Steeghs, N., Houdt, W.J. van, Brakenhoff, R.H., Sonke, G.S., Verheul, H.M.W., Giovannetti, E., Kazemier, G., Sabrkhany, S., Schuuring, E., and Sistermans, E.A.

Abstract

Contains fulltext : 281792.pdf (Publisher’s version ) (Open Access), Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for cancer detection, as they alter their RNA content upon local and systemic cues. We show that tumor-educated platelet (TEP) RNA-based blood tests enable the detection of 18 cancer types. With 99% specificity in asymptomatic controls, thromboSeq correctly detected the presence of cancer in two-thirds of 1,096 blood samples from stage I-IV cancer patients and in half of 352 stage I-III tumors. Symptomatic controls, including inflammatory and cardiovascular diseases, and benign tumors had increased false-positive test results with an average specificity of 78%. Moreover, thromboSeq determined the tumor site of origin in five different tumor types correctly in over 80% of the cancer patients. These results highlight the potential properties of TEP-derived RNA panels to supplement current approaches for blood-based cancer screening.

Published
2022

24. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry

Author

Smit, H.J.M., Aerts, J., Heuvel, M. van den, Hiltermann, T.J.N., Bahce, I., Smit, E.F., Dingemans, A.M.C., Hendriks, L.E., Stigt, J.A., Schramel, F.M.N.H., Tinteren, H. van, Groen, H.J.M., NVALT Immunotherapy Register, Pulmonary medicine, CCA - Cancer biology and immunology, Pulmonary Medicine, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Translational Immunology Groningen (TRIGR)

Subjects
0301 basic medicine, Male, Cancer Research, Lung Neoplasms, medicine.medical_treatment, Disease, THERAPY, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Registries, Immune Checkpoint Inhibitors, Netherlands, Response rate (survey), Aged, 80 and over, DOCETAXEL, Brain Neoplasms, Middle Aged, Prognosis, Survival Rate, Oncology, Docetaxel, 030220 oncology & carcinogenesis, SAFETY, Carcinoma, Squamous Cell, Population study, Female, Immunotherapy, Nivolumab, medicine.drug, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, Underrepresented population, Adenocarcinoma of Lung, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], 03 medical and health sciences, ADVANCED MELANOMA, SDG 3 - Good Health and Well-being, Internal medicine, ANTI-PD-1, medicine, Humans, Check point inhibitors, Lung cancer, Aged, business.industry, NIVOLUMAB, medicine.disease, Small Cell Lung Carcinoma, Clinical trial, 030104 developmental biology, Advanced non-small cell lung cancer, business, Follow-Up Studies
Abstract

Contains fulltext : 229865.pdf (Publisher’s version ) (Open Access) OBJECTIVE: Phase III studies of checkpoint inhibitors changed the therapeutic landscape for lung cancer. In 2015 the Dutch Society of Chest Physicians (NVALT) introduced a national immunotherapy registry for patients with lung cancer; quality standards for hospitals were implemented. At population level we studied clinical benefit in daily practice and in patients who are underrepresented in phase III trials. MATERIALS AND METHODS: From the initial introduction of checkpoint inhibitors in the Netherlands patients were centrally registered. Educational programs and quality control were provided under supervision of NVALT. The largest immunotherapy providing hospitals were compared to hospitals who provided less checkpoint inhibitors as marker of experience. Patients characteristics, treatment and side effects, response rate and survival were studied. RESULTS: A total of 2676 patients were registered, 2302 with follow up data were evaluated. Between October 2015 and December 2017 a gradual increase from 12 to 30 qualified hospitals showed no major toxicity differences. Toxicity led to a hospital admission rate of 9.1 with an average duration of 10.4 days. Overall tumor response was 21.8 % and median overall survival 12.6 months. Overall survival was not significantly different for patients aged ≥ 75 years, those having brain metastases or selected auto-immune diseases before start checkpoint inhibitors compared to younger patients or those without, respectively. Survival outcomes were worse in patients with PS 2+, non-smokers, and patients who received any palliative radiotherapy (HR 2.1, 95 % CI 1.7-2.7; 1.3, 95 % CI 1.0-1.6 and 1.2, 95 % CI 1.1-1.4, respectively). CONCLUSIONS: Changes in the therapeutic landscape did not lead to major differences in quality of care between hospitals. Elderly patients, those with brain metastases or selected auto-immune disease underrepresented in clinical trials did not do worse on checkpoint inhibitors, except for those with PS 2 + .

Published
2020

25. Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early stage NSCLC: The DIRECT-trial

Author

Dickhoff, C., Senan, S., Schneiders, F. L., Veltman, J., Hashemi, S., Fransen, M., Heineman, D., Radonic, T., van de Ven, P., Bartelink, I. H., Meijboom, L., Oprea-Lager, D., Garcia-Vallejo, J., Bouwhuis, N., de Gruijl, T. D., Bahce, I., Cardio-thoracic surgery, Surgery, CCA - Cancer Treatment and quality of life, Radiation Oncology, AII - Cancer immunology, Pulmonary medicine, Pathology, Epidemiology and Data Science, Clinical pharmacology and pharmacy, Radiology and nuclear medicine, Molecular cell biology and Immunology, and Medical oncology laboratory

Published
2021

26. 119TiP Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early stage NSCLC: The DIRECT-trial

Author

Dickhoff, C., primary, Senan, S., additional, Schneiders, F.L., additional, Veltman, J., additional, Hashemi, S., additional, Fransen, M., additional, Heineman, D., additional, Radonic, T., additional, van de Ven, P., additional, Bartelink, I.H., additional, Meijboom, L., additional, Oprea-Lager, D., additional, Garcia-Vallejo, J., additional, Bouwhuis, N., additional, de Gruijl, T.D., additional, and Bahce, I., additional

Published
2021
Full Text
View/download PDF

28. Treatment Recommendations for Stage III NSCLC by 3 Dutch Multidisciplinary Tumor Boards Prior To, and Following the PACIFIC Trial

Author

Ronden, M., Bahce, I., Claessens, N., Barlo, N., Dahele, M., Daniels, J., Tissing-Tan, C., Hekma, E., Hashemi, S. M. S., Van Der Wel, A., Spoelstra, F., Verbakel, W., Tiemessen, M., Van Laren, M., Becker, A., Tarasevych, S., Haasbeek, C., Van Den Brink, K. Maassen, Dickhoff, C., Senan, S., Radiation Oncology, Pulmonary medicine, CCA - Cancer Treatment and quality of life, Cardio-thoracic surgery, APH - Personalized Medicine, and APH - Quality of Care

Published
2021

33. MA06.06 Treatment Recommendations for Stage III NSCLC by 3 Dutch Multidisciplinary Tumor Boards Prior To, and Following the PACIFIC Trial

Author

Ronden, M., primary, Bahce, I., additional, Claessens, N., additional, Barlo, N., additional, Dahele, M., additional, Daniels, J., additional, Tissing-Tan, C., additional, Hekma, E., additional, Hashemi, S.M.S., additional, Van Der Wel, A., additional, Spoelstra, F., additional, Verbakel, W., additional, Tiemessen, M., additional, Van Laren, M., additional, Becker, A., additional, Tarasevych, S., additional, Haasbeek, C., additional, Van Den Brink, K. Maassen, additional, Dickhoff, C., additional, and Senan, S., additional

Published
2021
Full Text
View/download PDF

35. PD-0743 Treatment patterns for adrenal metastases in the era of MR-guided stereotactic ablative radiotherapy

Author

van Vliet, C., primary, Schneiders, F., additional, Engelsman, A., additional, Hashemi, S., additional, Bahce, I., additional, Haasbeek, C., additional, Bruynzeel, A., additional, Lagerwaard, F., additional, Palacios, M., additional, Becker-Commissaris, A., additional, Slotman, B., additional, Dickhoff, C., additional, and Senan, S., additional

Published
2021
Full Text
View/download PDF

36. Translation of third and second harmonic generation microscopy into the clinic for the assessment of fresh lung tumor tissue

Author

Van Huizen, L.M.G., Daniels, J.M.A., Radonic, T., van Mourik, F., Dickhoff, C., Bahce, I., Annema, J.T., Groot, M.L., Huang, Zhiwei, Lilge, Lothar D., Huang, Zhiwei, Lilge, Lothar D., Pulmonology, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, Biophotonics and Medical Imaging, LaserLaB - Biophotonics and Microscopy, Amsterdam Neuroscience - Brain Imaging, Pulmonary medicine, CCA - Cancer Treatment and quality of life, Pathology, Cardio-thoracic surgery, Surgery, and VU University medical center

Abstract

We show a portable third and second harmonic generation microscope in the clinic generating 3D real-time high resolution images of fresh lung tumor tissue providing immediate pathological feedback for clinicians potentially reducing endoscopy/operation time.

Published
2021

37. A nationwide population-based cohort study of surgical care for patients with superior sulcus tumors:Results from the Dutch Lung Cancer Audit for Surgery (DLCA-S)

Author

Winkelman, J. A., van der Woude, L., Heineman, D. J., Bahce, I., Damhuis, R. A., Mahtab, E. A.F., Hartemink, K. J., Senan, S., Maat, A. P.W.M., Braun, J., Paul, M. A., Dahele, M., Dickhoff, C., Winkelman, J. A., van der Woude, L., Heineman, D. J., Bahce, I., Damhuis, R. A., Mahtab, E. A.F., Hartemink, K. J., Senan, S., Maat, A. P.W.M., Braun, J., Paul, M. A., Dahele, M., and Dickhoff, C.

Abstract

Objectives: Data on national patterns of care for patients with superior sulcus tumors (SST) is currently lacking. We investigated the distribution of surgical care and outcome for patients with SST in the Netherlands. Material and methods: Data was retrieved from the Dutch Lung Cancer Audit for Surgery (DLCA-S) for all patients undergoing resection for clinical stage IIB-IV SST from 2012 to 2019. Because DLCA-S is not linked to survival data, survival for a separate cohort (2015–2017) was obtained from the Netherlands Cancer Registry (NCR). Results: In the study period, 181 patients had SST surgery, representing 1.03% (181/17488) of all lung cancer pulmonary resections. For 2015–2017, the SST resection rate was 14.4% (79/549), and patients with stage IIB/III SST treated with trimodality had a 3-year overall survival of 67.4%. 63.5% of patients were male, and median age was 60 years. Almost 3/4 of tumors were right sided. Surgery was performed in 20 hospitals, with average number of annual resections ranging from ≤ 1 (n = 17) to 9 (n = 1). 39.8% of resections were performed in 1 center and 63.5% in the 3 most active centers. 12.7% of resections were extended (e.g. vertebral resection). 85.1% of resections were complete (R0). Morbidity and 30-day mortality were 51.4% and 3.3% respectively. Despite treating patients with a higher ECOG performance score and more extended resections, the highest volume center had rates of morbidity/mortality, and length of hospital stay that were comparable to those of the medium volume (n = 2) and low-volume centers (n = 1). Conclusion: In the Netherlands, surgery for SST accounts for about 1% of all lung cancer pulmonary resections, the number of SST resections/hospital/year varies widely, with most centers performing an average of ≤ 1/year. Morbidity and mortality are acceptable and survival compares favourably with the literature. Although further centralisation is possible, it is unknown whether this will improve outcomes.

Published
2021

40. 1445P A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis

Author

Houda, I., Ulas, E.B., Hashemi, S.M.S., Becker, A., Daniels, H.M.A., Tarasevych, S., Looysen, E., Kunst, P., Moons-Pasic, A., Thönissen, N., van Haarst, J.M.W., van Tilburg, P., van der Maat, B., Barlo, N., Disselhorst, M., van Diepen, V., Tiemessen, M., van Laren, M., Veltman, J., and Bahce, I.

Published
2023
Full Text
View/download PDF

41. Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study

Author

Hashemi, S., primary, Fransen, M.F., additional, Niemeijer, A., additional, Ben Taleb, N., additional, Houda, I., additional, Veltman, J., additional, Becker- Commissaris, A., additional, Daniels, H., additional, Crombag, L., additional, Radonic, T., additional, Jongeneel, G., additional, Tarasevych, S., additional, Looysen, E., additional, van Laren, M., additional, Tiemessen, M., additional, van Diepen, V., additional, Maassen-van den Brink, K., additional, Thunnissen, E., additional, and Bahce, I., additional

Published
2021
Full Text
View/download PDF

42. P18.02 Factors Influencing Multi-Disciplinary Tumor Board Recommendations in Stage III Non-Small Cell Lung Cancer

Author

Ronden, M., primary, Bahce, I., additional, Hashemi, S., additional, Paul, M., additional, De Haan, P., additional, Becker, A., additional, Spoelstra, F., additional, Dahele, M., additional, Dickhoff, C., additional, Tiemessen, M., additional, Van Diepen, D., additional, Tarasevych, S., additional, Looysen, E., additional, Van Den Brink, K. Maassen, additional, Haasbeek, N., additional, Daniels, J., additional, Van Laren, M., additional, Roeleveld, R., additional, Alberts, B., additional, De Fraiture, D., additional, Veltman, J., additional, Verbakel, W., additional, and Senan, S., additional

Published
2021
Full Text
View/download PDF

44. Early mortality in stage III NSCLC after radical non-surgical therapy following ESMO guidelines

Author

Ronden-Kianoush, M., de Vries, I. F. Remmerts, Bahce, I., De Haan, P. F., Tiemessen, M. A., Spoelstra, F. O. B., Van Diepen, V. D. M., Haasbeek, C. J. A., Tarasevych, S., Daniels, H. J. M. A., Dahele, M. R., Hashemi, S. M., Becker, A., Veltman, J. D., Crombag, L. M. M., Senan, S., Verbakel, W. F. A. R., Radiation Oncology, Pulmonary medicine, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, CCA - Imaging and biomarkers, APH - Personalized Medicine, and APH - Quality of Care

Published
2020

45. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry

Author

Smit, H.J., Aerts, J., Heuvel, M. van den, Hiltermann, T.J.N., Bahce, I., Smit, E.F., Dingemans, A.M., Hendriks, L.E., Stigt, J.A., Schramel, F.M., Tinteren, H. van, Groen, H.J.M., of, N.I.R. all participant, Smit, H.J., Aerts, J., Heuvel, M. van den, Hiltermann, T.J.N., Bahce, I., Smit, E.F., Dingemans, A.M., Hendriks, L.E., Stigt, J.A., Schramel, F.M., Tinteren, H. van, Groen, H.J.M., and of, N.I.R. all participant

Abstract

Contains fulltext : 229865.pdf (Publisher’s version ) (Open Access), OBJECTIVE: Phase III studies of checkpoint inhibitors changed the therapeutic landscape for lung cancer. In 2015 the Dutch Society of Chest Physicians (NVALT) introduced a national immunotherapy registry for patients with lung cancer; quality standards for hospitals were implemented. At population level we studied clinical benefit in daily practice and in patients who are underrepresented in phase III trials. MATERIALS AND METHODS: From the initial introduction of checkpoint inhibitors in the Netherlands patients were centrally registered. Educational programs and quality control were provided under supervision of NVALT. The largest immunotherapy providing hospitals were compared to hospitals who provided less checkpoint inhibitors as marker of experience. Patients characteristics, treatment and side effects, response rate and survival were studied. RESULTS: A total of 2676 patients were registered, 2302 with follow up data were evaluated. Between October 2015 and December 2017 a gradual increase from 12 to 30 qualified hospitals showed no major toxicity differences. Toxicity led to a hospital admission rate of 9.1 with an average duration of 10.4 days. Overall tumor response was 21.8 % and median overall survival 12.6 months. Overall survival was not significantly different for patients aged ≥ 75 years, those having brain metastases or selected auto-immune diseases before start checkpoint inhibitors compared to younger patients or those without, respectively. Survival outcomes were worse in patients with PS 2+, non-smokers, and patients who received any palliative radiotherapy (HR 2.1, 95 % CI 1.7-2.7; 1.3, 95 % CI 1.0-1.6 and 1.2, 95 % CI 1.1-1.4, respectively). CONCLUSIONS: Changes in the therapeutic landscape did not lead to major differences in quality of care between hospitals. Elderly patients, those with brain metastases or selected auto-immune disease underrepresented in clinical trials did not do worse on checkpoint inhibitors, except for those with PS 2 +

Published
2020

48. PO-0996: Early mortality in stage III NSCLC after radical non-surgical therapy following ESMO guidelines

Author

Ronden-Kianoush, M., primary, de Vries, I.F. Remmerts, additional, Bahce, I., additional, De Haan, P.F., additional, Tiemessen, M.A., additional, Spoelstra, F.O.B., additional, Van Diepen, V.D.M., additional, Haasbeek, C.J.A., additional, Tarasevych, S., additional, Daniels, H.J.M.A., additional, Dahele, M.R., additional, Hashemi, S.M., additional, Becker, A., additional, Veltman, J.D., additional, Crombag, L.M.M., additional, Senan, S., additional, and Verbakel, W.F.A.R., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results